| 2025-12-24 |
复牌提示：
2025-12-23 17:59:25 停牌，复牌日期 2025-12-24 07:05:00
|
| 2025-11-12 |
详情>>
内部人交易：
Scadden David共交易2笔
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本5831.38万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-5.27美元,归母净利润-3.05亿美元,同比去年增长-139.56%
|
| 2025-10-30 |
财报披露：
美东时间 2025-10-30 盘前发布财报
|
| 2025-07-31 |
详情>>
业绩披露：
2025年中报每股收益-3.49美元,归母净利润-2.01亿美元,同比去年增长-13.31%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-1.55美元,归母净利润-8928.9万美元,同比去年增长-9.49%
|
| 2025-04-25 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To approve an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, to increase the number of shares of common stock available thereunder by 2,500,000 shares;
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
5.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2025-02-13 |
详情>>
业绩披露：
2022年年报每股收益-4.23美元,归母净利润-2.32亿美元,同比去年增长-114.44%
|
| 2025-02-13 |
详情>>
业绩披露：
2024年年报每股收益11.86美元,归母净利润6.74亿美元,同比去年增长291.35%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益13.58美元,归母净利润7.70亿美元,同比去年增长400.70%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益-2.97美元,归母净利润-1.65亿美元,同比去年增长11.66%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-3.14美元,归母净利润-1.78亿美元,同比去年增长-7.79%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-1.45美元,归母净利润-8154.9万美元,同比去年增长-0.66%
|
| 2024-04-26 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2024-02-15 |
详情>>
业绩披露：
2023年年报每股收益-6.33美元,归母净利润-3.52亿美元,同比去年增长-51.89%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-4.61美元,归母净利润-2.56亿美元,同比去年增长4.54%
|
| 2023-04-26 |
股东大会：
将于2023-06-13召开股东大会
会议内容 ▼▲
- 1.To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To approve the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan;
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2022-04-28 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.To elect each of the three Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers;
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
5.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-08 |
股东大会：
将于2021-05-20召开股东大会
会议内容 ▼▲
- 1.To elect each of the three Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2021-02-11 |
股东大会：
将于2021-03-25召开股东大会
会议内容 ▼▲
- 1.consider and vote upon the proposal to approve the proposed sale of the Company’s commercial, clinical and research-stage oncology portfolio (the “oncology business”) to Servier Pharmaceuticals, LLC (“Servier”) pursuant to the terms of the Purchase and Sale Agreement, dated as of December 20, 2020 (the “purchase agreement”), by and among Agios, Servier and Servier S.A.S. (“Servier Parent”).
|
| 2020-04-16 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect each of the two Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2023 annual meeting of stockholders and until his respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2019-04-18 |
股东大会：
将于2019-05-29召开股东大会
会议内容 ▼▲
- 1.To elect each of the three Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2022 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2018-04-18 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.To elect each of the three Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2021 annual meeting of stockholders and until his or her respective successor is duly elected and qualified;
2.To vote, on an advisory basis, to approve the compensation paid to our named executive officers;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
4.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2017-04-24 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders and until his respective successor is duly elected and qualified;
2.To approve an advisory vote on the compensation paid to our named executive officers;
3.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2016-04-27 |
股东大会：
将于2016-06-21召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, each to serve for a three-year term expiring at the 2019 annual meeting of stockholders and until his respective successor is duly elected and qualified;
2.To approve an advisory vote on the compensation paid to our named executive officers;
3.To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
5.To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|